Piper Jaffray Downgrades Amylin Pharmaceuticals (AMLN) to Neutral
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Piper Jaffray downgraded Amylin Pharmaceuticals (NASDAQ: AMLN) from Overweight to Neutral, maintains price target of $21.00.
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $15.39 yesterday.
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $15.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades Vicinity Centers (VCX:AU) (CNRAF) to Neutral
- Barclays Downgrades Renault SA (RNO:FP) (RNSDF) to Equalweight
- JPMorgan Downgrades Rockwool (ROCKB:DC) (RKWBF) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
